Tag: Roche

More than 25 brand-name and generic medications are currently approved for managing multiple sclerosis, with a diverse field of pharmaceutical companies dedicated to developing and manufacturing these vital treatments. This complex landscape is dominated by several major players who make MS drugs, alongside a growing number of smaller biotech firms.

First approved by the FDA in 1997, rituximab has since revolutionized the treatment of several B-cell cancers and autoimmune diseases. The journey to market involved multiple companies, and today, an expanding list of manufacturers produce this essential medicine. So, which company makes rituximab, and what do you need to know about the different versions?

In August 2024, Genentech confirmed the discontinuation of the HIV medication Fuzeon (enfuvirtide) in the United States, effective February 28, 2025. This change is primarily driven by evolving clinical practices and a reduced medical need for the drug, with numerous newer alternative treatments now available.

According to official product information and pharmaceutical databases, the pharmaceutical company **Roche** is the manufacturer of Ristova. This medication, with the generic name Rituximab, is a crucial therapy used for treating certain blood cancers and autoimmune disorders.

Rozlytrek (entrectinib) received its initial accelerated approval from the U.S. Food and Drug Administration (FDA) in August 2019 for specific types of cancer. The answer to who makes Rozlytrek involves a complex history of development and acquisition, leading to the current manufacturer, Genentech, a member of the Roche Group.